Tags : NGM

Merck Extends its Strategic Collaboration with NGM Biopharmaceuticals

Shots: Merck exercises its option to extend its Feb,2015 agreement with NGM for development and commercialization of novel biologics therapies. NGM to receive $20M as an extension fee for R&D activities during the two-year extension period in Mar 2021 & 2022 As part of the collaboration, in Jan,2019 Merck in-licensed NGM’s NASH therapy NGM313 (MK-3655), […]Read More

Merck Exercises its Option to License NGM’s NGM313 (MK-3655) for

Shots:  NGM to receive $20M as total deal value with anoption to participate in P-III trial of MK-3655 with equal cost and revenue sharing. Merck to get exclusive worldwide rights to develop and commercialize NGM’s NGM313 (currently MK-3655) If the option is not exercised by NGM, it will receive milestones and royalties on sales of […]Read More